Heart ultrasound study in multiple myeloma treated with RVd
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how a new heart ultrasound test can measure heart side effects and overall outcomes in people with multiple myeloma who are treated with the RVd drug combination. It may help doctors better understand heart risks during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have multiple myeloma (a blood cancer that affects plasma cells)
- You plan to receive RVd therapy (a three-drug combination: lenalidomide, bortezomib, and dexamethasone) during a hospital stay
- You can complete at least 3 to 4 cycles of treatment
- You do not have amyloidosis (protein buildup in organs) or serious heart conditions like heart attack, heart failure, atrial fibrillation, or prior heart surgery
- Your heart ultrasound images are clear enough for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at heart health in adults with multiple myeloma who are starting a new treatment. It aims to see how the treatment affects the heart and to help manage any heart-related risks.
This trial tests a combination of three drugs (isatuximab, bortezomib, lenalidomide, and a steroid) for people with newly diagnosed multiple myeloma who are older or frail and cannot have a stem cell transplant. It focuses on those with a certain type of myeloma cell in their blood, to see if the treatment works well and is safe.
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.